Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoLIPA: Neoadjuvant LTX-315 + Pembrolizumab in Melanoma
NCT06651151Phase 2Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxotemitide in melanoma, sponsored by Oslo University Hospital. Primary endpoint: Complete Pathologic Response Rate at 12 weeks. Started Nov 2024; status: recruiting.
02
Drugs
ruxotemitide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06651151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651151.